Baidu
map

Int J Pediatr Otorhinolaryngol:中国汉族人口中,哮喘和过敏性鼻炎儿童FCRL3和FCRL5多样性遗传危害性研究

2019-03-02 AlexYang MedSci原创

哮喘和过敏性鼻炎(AR)常常是上呼吸道并发疾病。有研究表明,FCRL3和FCRL5基因的单核苷酸变异(SNPs)与各种免疫相关的障碍相关。最近,有研究人员在中国汉族人口中评估了FCRL3和FCRL5多样性与哮喘和过敏性鼻炎(AR)的相关性。研究发现,FCRL5基因中的rs6692977 CT基因型和T等位基因频率在哮喘和AR并发受试者中比健康对照显著更高(分别为Bonferroni-correct

哮喘和过敏性鼻炎(AR)常常是上呼吸道并发疾病。有研究表明,FCRL3和FCRL5基因的单核苷酸变异(SNPs)与各种免疫相关的障碍相关。最近,有研究人员在中国汉族人口中评估了FCRL3和FCRL5多样性与哮喘和过敏性鼻炎(AR)的相关性。

研究发现,FCRL5基因中的rs6692977 CT基因型和T等位基因频率在哮喘和AR并发受试者中比健康对照显著更高(分别为Bonferroni-corrected p (Pc)= 3.75×10-6; Pc=0.006),然而CC基因型和C等位基因则显著更低(分别为Pc=4.15×10-5; Pc=0.006)。另外,哮喘和并发AR受试者中,FCRL3基因中的rs7528684 A等位基因频率(Pc=1.80×10-3)和rs10489678G等位基因频率(Pc=0.04)均比对照显著更高。然而,测试的7个SNPs遗传多样性在哮喘和健康个体中没有差异。

最后,研究人员指出,他们的研究鉴定了FCRL3和FCRL5中新的SNPs,并且与受试者哮喘和并发AR风险显著相关。遗传变异也许在哮喘儿童的哮喘症状发展中具有作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047084, encodeId=a91f204e08479, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 21 19:51:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727909, encodeId=b4481e2790991, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 12 06:51:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639000, encodeId=14a616390005a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 18 12:51:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470938, encodeId=059414e0938db, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 04 06:51:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047084, encodeId=a91f204e08479, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 21 19:51:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727909, encodeId=b4481e2790991, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 12 06:51:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639000, encodeId=14a616390005a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 18 12:51:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470938, encodeId=059414e0938db, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 04 06:51:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-11-12 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047084, encodeId=a91f204e08479, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 21 19:51:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727909, encodeId=b4481e2790991, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 12 06:51:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639000, encodeId=14a616390005a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 18 12:51:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470938, encodeId=059414e0938db, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 04 06:51:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047084, encodeId=a91f204e08479, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 21 19:51:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727909, encodeId=b4481e2790991, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 12 06:51:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639000, encodeId=14a616390005a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat May 18 12:51:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470938, encodeId=059414e0938db, content=<a href='/topic/show?id=507043296fe' target=_blank style='color:#2F92EE;'>#多样性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43296, encryptionId=507043296fe, topicName=多样性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 04 06:51:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]

相关资讯

Environ Int:室内外颗粒物和空气污染与学前儿童哮喘、喘息、湿疹和鼻炎相关性分析

最近,有研究人员研究了室内颗粒物质(PM)、室外空气污染和抗生素使用与学龄前儿童哮喘、鼻炎和湿疹之间的关系,并调查了PM与抗生素使用之间的协同作用。研究包括了39782名来自中国7个城市的年龄在3-6岁的儿童。环境温度和空气污染数据来自当地监测站。室内PM来源数据(ETS,烧香或蚊香、以及做饭燃烧的生物质)、抗生素的使用和健康通过父母调查问卷来进行评估,并通过多水平逻辑回归来对相关性进行计算。研究

Int Arch Allergy Immunol:新鼻内喷雾配方-盐酸氮卓斯汀和氟替卡松丙酸酯在治疗季节过敏性鼻炎中的疗效研究

最近,有研究人员比较了新鼻内喷雾配方(MP-AzeFlu)-盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP)与一线鼻内抗组胺喷雾(AZE)在治疗季节过敏性鼻炎(SAR)患者中的效果情况。研究人员将中度到重度SAR/鼻结膜炎患者(n=149;年龄在18-65岁)随机分配接受MP-AzeFlu(每次喷雾137/50 μg AZE/FP)或者AZE(137 μg/每次喷雾)治疗。主要的结果为早上基线点到晚

盘点:近期鼻炎相关机制盘点

【1】Am J Rhinol Allergy:MIR-17-5P在季节过敏性鼻炎病理中的作用研究https://www.ncbi.nlm.nih.gov/pubmed/30616374作为最流行的鼻炎类型,过敏性鼻炎包括了季节过敏性鼻炎(SAR)和永久过敏性鼻炎。最近,有研究人员尝试阐释SAR的机制。研究人员从基因表达综合数据库中提取了基因芯片数据集GSE43523(包括了7个SAR鼻上皮细胞

Sci Rep:过敏性鼻炎和中耳炎相关性分析

尽管许多研究报道了儿童中,过敏性鼻炎是一个独立的风险因子并与中耳炎高度相关,然而,仍旧缺乏关于人口统计学的流行病学研究。最近,有研究人员在韩国当地人口中,使用全国的调查数据鉴定了是否在年龄为7-12岁的儿童中,过敏性鼻炎是中耳炎的独立风险因子。研究包括了472名儿童(248名男性和224名女性),他们在2015年完成了韩国国家健康与营养调查。中耳炎由耳鼻喉科专家使用鼓室测量、听力测量和耳镜检查来鉴

Eur Arch Otorhinolaryngol:miR-181a和miR-155的减少与Treg细胞数的减少和功能有关

之前的研究表明调节细胞(Tregs)参与了过敏性气道炎症过程。最近,有研究人员评估了miRNA在AR儿童中的表达并探索了与Tregs和AR严重度的相关性。研究包括了25名AR儿童和20名健康的儿童作为对照。研究人员利用流式细胞术和没脸免疫反应对Treg细胞的比例和IL-10和TGF-β的表达进行了检测名,并进行了microRNA芯片分析了差异表达分析。研究发现,患有AR的儿童的Tregs比例和IL

盘点:近期鼻炎与治疗盘点

【1】Medicine (Baltimore):针灸在过敏性鼻炎患者中的治疗效果研究https://www.ncbi.nlm.nih.gov/pubmed/30608427最近,有研究人员在舌下特异性过敏原免疫治疗(SASIT)的过敏性鼻炎(AR)患者中,回顾性的分析了针灸疗法作为一种附加的疗法(AAOT)对过敏性鼻炎患者的治疗效果。研究总共包括了120名符合研究标准的AR成年人患者。其中60

Baidu
map
Baidu
map
Baidu
map